Tempus Labs

Chicago, Illinois, U.S. All United States companies → — Founded 2015

Point-of-Care Diagnostics Specialty-Focused AI

Laboratory Medicine Oncology Pathology

Lab & Diagnostics Oncology AI

Public (IPO on June 14, 2024)

Claim this company

About Tempus Labs

Tempus Labs, now known as Tempus AI, is an American health technology company that leverages data and artificial intelligence (AI) to advance precision medicine. The company was founded in 2015 by Eric Lefkofsky, inspired by his wife’s breast cancer diagnosis and the observed shortcomings in data-driven oncology care. Tempus aims to provide physicians with near real-time, data-driven insights to deliver personalized patient care and facilitate the discovery, development, and delivery of optimal therapeutics.

For physicians, Tempus offers a comprehensive platform that integrates clinical and molecular data to inform diagnoses and treatment strategies across various disease areas. Initially focused on oncology, Tempus has expanded its capabilities to include cardiology, radiology, and neuropsychiatry (such as depression, anxiety, and ADHD). Their services include genome sequencing, AI-enabled diagnostics, and pharmacogenomic testing. Tempus also provides solutions for clinical research, including clinical trial recruitment and real-world data analysis, partnering with life sciences companies to accelerate drug development. The company’s offerings are designed to turn complex data into clear, usable insights, supporting more precise and personalized care.

What Physicians Need to Know

Specialization

Tempus Labs specializes in AI-powered precision medicine, primarily in oncology, but has expanded into neurology, cardiology, infectious disease, and psychiatry. They focus on integrating molecular and clinical data to provide personalized treatment insights.

Key Differentiators

Tempus differentiates itself through its control of the diagnostic workflow and direct data generation, creating one of the world's largest libraries of clinical and molecular data. They combine this multimodal data with AI to offer intelligent diagnostics, clinical trial matching, and decision support tools.

Technology Stack

Tempus utilizes a robust technology stack including programming languages like Node.js, Python, and TypeScript. For development, they use Docker, and for libraries, React and jQuery. Their data stores include MySQL and Sequelize, and for analytics, they leverage Tableau and Looker. They also employ generative AI and large language models (LLMs) for data analysis and clinical decision support.

Data & AI Capabilities

Tempus has built robust, secure data pipelines with over 4,500 hospitals in the U.S., enabling them to ingest, structure, and harmonize multimodal data at an unprecedented scale. Their dataset includes approximately 38 million research records, over 7 billion clinical notes, and more than a million cancer patients with rich molecular profiling. They also have approximately 1.9 billion radiology images across various specialties. Tempus uses AI to transform unstructured clinical text into analysis-ready real-world data.

Products & Applications

Key products include Tempus Platform, Tempus One (an AI-enabled clinical assistant), Tempus Next (an AI-enabled care pathway platform), Olivia, and Lens (an agentic platform for oncology drug development). These tools aid in predictive insights, molecular profiling, care gap identification, and clinical trial optimization.

Physician Tip

Tempus AI empowers physicians by providing personalized, data-driven insights for treatment decisions, especially in oncology. Their seamless EHR integration reduces cognitive load and allows rapid access to patient reports, biomarker status, and medical history. Physicians can use Tempus to better understand molecular drivers of cancer, identify targeted therapies, explore immunotherapy options, and assess eligibility for clinical trials. The platform aims to provide actionable information in a clear, physician-friendly format, helping to move from 'what is wrong?' to 'what is the best treatment for you?'. Generative AI tools like Tempus One allow physicians to query millions of unstructured documents for research and clinical care, extracting key clinical events and creating a longitudinal view of patient histories.

Tempus excels in seamless EHR integration, allowing oncologists to access patient reports and biomarker status directly within their existing workflows. They utilize HL7 and FHIR interfaces for near real-time transfer of structured data and Secure Data Exchange (SDX) for efficient batch transfers of high-volume documents and historical records. This approach centralizes diverse data streams into a single orchestration layer, reducing the IT burden on healthcare sites.

Products by Tempus Labs

No products listed for this company yet. Know of one? Suggest it →

What the Web Says

Tempus Labs is a biotechnology company focused on precision medicine, utilizing AI to analyze clinical and molecular data for personalized healthcare treatments, particularly in oncology, neurology, psychiatry, and cardiology. While the company is praised for its impactful mission and innovative approach to healthcare, employee and product reviews present a mixed picture. Many employees appreciate the meaningful work and collaborative environment, but concerns are frequently raised about management, work-life balance, and compensation. Product reviews indicate that while the genomic testing can be beneficial for treatment decisions, some users have experienced difficulties with customer service and report interpretation.

Overall: Mixed

Strengths

Meaningful work and impactful mission in precision medicine.
Collaborative environment and smart colleagues.
Opportunities for learning and professional growth in rapidly evolving fields.
Advanced genomic testing for personalized treatment in cancer and mental health.
Strong focus on data integration and AI application in healthcare.
Offers comprehensive healthcare coverage and other benefits.

Limitations

Disorganized and toxic management.
Poor work-life balance.
Issues with compensation and lack of 401k match.
Difficulties with product report interpretation and customer service for patients.
Lack of clear feedback and support for neurodivergent employees.
Outdated technology in some lab operations.

Based on reviews from: Indeed.com, Reddit.com, BuiltIn.com, Nebula.org, Dennis Gong (Personal Blog), Capterra, G2, BBB.org

Last updated: 2026-10-17

Videos

News, demos, and interviews about Tempus Labs.

Loading videos...

Videos load interactively. If none appear, search YouTube for Tempus Labs →

View all on YouTube

Press & Coverage

Tempus AI

Tempus Announces Multi-Year Collaboration with Moderna and Merck

Tempus announced an expanded, multi-year collaboration with Moderna and Merck to support the potential commercialization of intismeran autogene (V940/mRNA-4157), an individualized neoantigen therapy. Tempus will manage sample collection and transfer, and provide next-generation sequencing services.

2026-10

Tempus AI

Tempus Announces 13 Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2026

Tempus AI, Inc. announced that 13 abstracts have been accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2026, taking place in Madrid.

2026-10

Tempus AI

Tempus Receives FDA Clearance for its ECG-MR AI Product Designed to Identify Undiagnosed Mitral Regurgitation

Tempus received 510(k) clearance from the U.S. Food and Drug Administration for Tempus ECG-MR, an AI product that analyzes standard 12-lead resting electrocardiograms (ECGs) to detect signs associated with undiagnosed moderate or severe mitral regurgitation.

2026-09

Tempus AI

Tempus and Recursion Extend Existing Data License Agreement and Enter New License Agreement for Recursion's RNA Foundation Model

Tempus announced an extension of its data license agreement with Recursion Pharmaceuticals through November 2029, and a new agreement under which Tempus will license Recursion's TxFM RNA foundation model.

2026-09

Tempus AI

Tempus Secures Up to $9.5 Million in ARPA-H ADVOCATE Funding to Deploy First Autonomous AI in Cardiology

Tempus has been selected by ARPA-H to receive an award of up to $9.5 million to build the first autonomous clinical AI agent capable of providing safe and effective care to patients suffering from heart failure.

2026-09

Tempus AI

Tempus Launches Effort to Build the Largest Multimodal Whole-Genome Dataset to Advance AI-driven Healthcare Innovation

Tempus announced an initiative to build a research platform containing 100,000 whole genomes linked to longitudinal clinical information, creating the first de-identified multimodal whole-genome sequencing dataset built around disease populations and patient outcomes.

2026-09

Tempus AI

Tempus Receives FDA Clearance for its AI Product Intended to Detect Signs of Pulmonary Hypertension From Standard ECGs

Tempus AI, Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Tempus ECG-PH, an AI-enabled software device that analyzes standard 12-lead electrocardiograms (ECGs) for signs associated with pulmonary hypertension.

2026-08

Tempus AI

Tempus Announces National Launch of OneOme Pharmacogenomics Testing, Advancing Patient Safety and Precision Medicine

Tempus AI, Inc. announced the national launch of its OneOme pharmacogenomics (PGx) testing solution, delivering advanced genetic insights to optimize medication safety, dosing, and toxicity risk assessment.

2026-07

Frequently Asked Questions

What specific AI-powered products and services does Tempus Labs offer that are relevant to my clinical practice or hospital system?

Tempus Labs provides AI-powered solutions primarily focused on precision medicine, including genomic sequencing and analysis of patient data to inform treatment decisions, particularly in oncology. Their platform integrates molecular and clinical data to offer insights for personalized patient care and research.

How does Tempus Labs ensure the privacy and security of patient data, and what compliance standards (e.g., HIPAA, GDPR) do they adhere to?

Tempus Labs prioritizes data privacy and security, adhering to strict compliance standards such as HIPAA. They employ robust de-identification and security protocols to protect patient information while leveraging it for research and clinical insights.

Can you explain Tempus Labs' pricing model for your AI solutions and how it would integrate with our existing healthcare IT budget and billing processes?

Tempus Labs' pricing model can vary depending on the specific services and scale of implementation, often involving per-test fees for genomic profiling or subscription models for their data and analytics platforms. Detailed pricing and integration discussions are typically handled directly with their sales team to align with an institution's budget and billing.

What kind of support and training does Tempus Labs provide for physicians and healthcare administrators to effectively utilize their AI platforms?

Tempus Labs offers comprehensive support and training, including dedicated account management, scientific and technical support, and educational resources to help healthcare professionals effectively integrate and utilize their AI platforms in clinical workflows and research.

What partnerships does Tempus Labs have with other healthcare organizations, academic institutions, or pharmaceutical companies, and how do these benefit my practice?

Tempus Labs collaborates with numerous healthcare organizations, academic institutions, and pharmaceutical companies to advance precision medicine and research. These partnerships can provide access to cutting-edge research, clinical trials, and a broader understanding of treatment efficacy, ultimately benefiting patient care.

Given the rapid evolution of AI in healthcare, what is Tempus Labs' long-term vision and how do they ensure the stability and continuous innovation of their offerings?

Tempus Labs is committed to continuous innovation in healthcare AI, with a long-term vision to make precision medicine a reality for every patient. They invest heavily in research and development, constantly expanding their data sets and refining their AI algorithms to ensure the stability and advancement of their offerings.

How does Tempus Labs validate the clinical utility and efficacy of its AI-driven insights and recommendations?

Tempus Labs validates its AI-driven insights through rigorous scientific methods, including extensive data analysis, peer-reviewed publications, and collaborations with leading cancer centers and researchers. Their focus is on generating evidence that demonstrates the clinical utility and efficacy of their genomic and phenotypic data in guiding treatment decisions.